Personalis (PSNL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +16.13%. A quarter ago, it was expected that this provider of contract research and genomic information would post a loss of $0.28 per share when it actually produced a loss of $0.24, delivering a surprise of +14.29%.Over the ...

Core Viewpoint - Gilead Sciences, Inc. reported strong fourth-quarter results for 2025, with adjusted earnings per share (EPS) of $1.86, exceeding estimates, while total revenues of $7.9 billion also surpassed expectations, driven by growth in HIV and Liver Disease drugs [1][4][6]. Financial Performance - Adjusted EPS for Q4 2025 was $1.86, beating the Zacks Consensus Estimate of $1.83, but down from $1.90 a year ago due to higher acquired IPR&D expenses [1][6]. - Total revenues reached $7.9 billion, a 5% increase year over year, surpassing the Zacks Consensus Estimate of $7.6 billion [1][4]. - Product sales increased by 5% year over year to $7.9 billion, with HIV product sales growing 6% to $5.8 billion [4][5]. Product Sales Breakdown - Biktarvy sales rose 5% year over year to $4 billion, capturing over 52% of the U.S. HIV treatment market [5][6]. - Descovy sales surged 33% year over year to $819 million, driven by increased demand for HIV prevention [6][7]. - Liver Disease portfolio sales increased 17% to $844 million, exceeding estimates, primarily due to demand for Livdelzi [8]. - Veklury sales fell 37% to $212 million, attributed to lower COVID-19 hospitalization rates [8]. Cost and Expenses - Adjusted product gross margin was 86.8%, slightly up from 86.7% year over year [11]. - Research and development expenses remained flat at $1.6 billion, while SG&A expenses decreased to $1.7 billion from $1.9 billion [11][12]. 2025 and 2026 Guidance - For 2025, revenues rose 2% year over year to $29.4 billion, exceeding estimates, with adjusted EPS increasing to $8.15 from $4.62 in 2024 [13]. - Gilead expects 2026 product sales between $29.6 billion and $30 billion, with adjusted EPS projected in the range of $8.45-$8.85 [14][15]. Pipeline and Regulatory Updates - Positive phase III results for the investigational regimen of bictegravir and lenacapavir were reported, with a potential launch targeted for the second half of the year [16][23]. - Gilead has discontinued several studies based on recommendations from independent committees, including the phase III STAR-221 study [18][19]. Market Position and Competitive Landscape - Gilead's HIV business exceeded management's growth target, driven by strong performances from Biktarvy and Descovy, despite competitive pressures [21][22]. - The company anticipates continued competitive pressures in cell therapies and expects to face headwinds from U.S. government drug pricing agreements [24][27].

Core Insights - Gilead Sciences has exercised its option to exclusively license Assembly Biosciences' herpes simplex virus helicase-primase inhibitor programs, marking the first advancement under their collaboration [1][2] Licensing Agreement - Gilead entered a 12-year partnership with Assembly Biosciences in 2023 to develop novel antiviral therapies, with Assembly Bio receiving a $35 million payment upon Gilead's exercise of its option [2] - Gilead will obtain exclusive rights to ABI-5366 and ABI-1179, taking full responsibility for their clinical development and commercialization [2] Financial Milestones - Assembly Biosciences is eligible for up to $330 million in regulatory and commercial milestones, along with tiered royalties on net sales [3][7] Product Development - ABI-1179 and ABI-5366 are long-acting helicase-primase inhibitors showing strong antiviral activity and significant reduction in virus-positive lesions in interim data from early-stage studies [8][9] - Over four million people in the U.S. and some European countries suffer from recurrent genital herpes, indicating a substantial market opportunity for these new therapies [9][10] Market Context - No new HSV therapies have been approved in the U.S. or Europe in over 25 years, highlighting the potential impact of ABI-5366 and ABI-1179 if successfully developed [9][10] Gilead's HIV Portfolio - Gilead has a leading HIV franchise, with products like Biktarvy and Descovy driving top-line growth [11] - The recent FDA approval of lenacapavir for HIV prevention enhances Gilead's portfolio, especially as Truvada faces generic competition [12]

Core Insights - Biotechnology stocks experienced significant movements in after-hours trading, with several companies reporting strong gains driven by positive trial results and strategic announcements [1] Company Performances - Exicure, Inc. (XCUR) saw a substantial increase of 72.61% to $9.20 after announcing positive Phase 2 trial results for burixafor, achieving a primary endpoint success rate of approximately 90% in multiple myeloma patients [2] - Artiva Biotherapeutics, Inc. (ARTV) rose 10.39% to $3.40 despite a regular session decline, with no new updates reported [3] - iBio, Inc. (IBIO) advanced 8.38% to $1.81, following a significant 39.17% increase during regular trading [3] - Cartesian Therapeutics, Inc. (RNAC) increased by 6.55% to $7.16, recovering from a prior decline [4] - Metagenomi, Inc. (MGX) gained 7.18% to $1.94, with plans to present preclinical data at an upcoming conference [5] - BioAtla, Inc. (BCAB) rose 4.81% to $0.85, despite no new updates [6] - ProMIS Neurosciences, Inc. (PMN) climbed 3.02% to $7.85, following a publication related to Alzheimer's disease biomarkers [7] - DiaMedica Therapeutics Inc. (DMAC) increased by 4.77% to $9.18, with no new announcements [8] - Wave Life Sciences Ltd. (WVE) shares surged 4.97% to $19.44 after a significant 147.26% increase during regular trading, linked to a $250 million public offering [9] - Assembly Biosciences, Inc. (ASMB) gained 5.96% to $37.49, reporting positive interim results from Phase 1b studies of HSV inhibitors [10]

Core Insights - Supernus Pharmaceuticals (SUPN) reported quarterly earnings of $1.01 per share, exceeding the Zacks Consensus Estimate of $0.82 per share, but down from $1.06 per share a year ago, resulting in an earnings surprise of +23.17% [1] - The company achieved revenues of $192.1 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.52% and showing an increase from $175.69 million year-over-year [2] - Supernus shares have increased approximately 54% year-to-date, significantly outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.62 on revenues of $208 million, while the estimate for the current fiscal year is $2.65 on revenues of $705.3 million [7] - The estimate revisions trend for Supernus was favorable prior to the earnings release, contributing to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which Supernus belongs, is currently ranked in the top 18% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - AxoGen, Inc. specializes in developing and marketing surgical solutions for peripheral nerve injuries, operating in the healthcare sector with a focus on nerve repair and protection [1] - The company faces competition from AtriCure, Tactile Systems Technology, BioLife Solutions, AnaptysBio, and Assembly Biosciences [1] Financial Performance - AxoGen's Return on Invested Capital (ROIC) is 2.07%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 8.72%, indicating inefficient capital utilization [2][5] - AtriCure has a negative ROIC of -6.47% and a WACC of 11.01%, resulting in a ROIC to WACC ratio of -0.59, suggesting struggles in generating returns above its cost of capital [3] - BioLife Solutions and AnaptysBio also report negative ROICs of -4.85% and -28.56%, respectively, with WACCs of 12.57% and 9.10% [3] - Assembly Biosciences shows the highest inefficiency with a ROIC of -127.67% and a WACC of 6.45%, leading to a ROIC to WACC ratio of -19.80 [4][5]

Core Insights - Assembly Biosciences, Inc. (NASDAQ:ASMB) is highlighted as a top long-term biotechnology stock to consider for investment [1] - H.C. Wainwright has reaffirmed a Buy rating and a price target of $50 for Assembly Biosciences following promising interim data for ABI-5366, an oral treatment for recurrent genital herpes [2] Company Overview - Assembly Biosciences focuses on developing and commercializing small-molecule therapies for serious viral diseases, particularly chronic hepatitis B virus (HBV) and herpesviruses [2] Clinical Development - The interim data presented for ABI-5366 demonstrated strong antiviral activity, favorable tolerability, and a dosing profile that supports weekly or monthly administration [2] - These results are seen as a validation of Assembly's helicase-primase inhibitor platform, reducing the risk associated with advancing ABI-5366 into Phase 2 trials [2] - The company plans to initiate Phase 2 clinical studies by mid-2026, indicating ongoing progress in its antiviral pipeline [2]

Core Insights - Successful investing requires understanding the fundamentals of owned stocks, as emphasized by Abigail Johnson, CEO of Fidelity Investments [1] Company Developments - Disc Medicine Inc. (IRON) has submitted a New Drug Application (NDA) for its lead drug candidate, Bitopertin, to the FDA for treating erythropoietic protoporphyria (EPP) [3][4] - The FDA is expected to decide on the NDA within 60 days of submission [3] - Disc Medicine received a Commissioner's National Priority Voucher (CNPV) for Bitopertin, expediting the review process to 1-2 months [5] - The stock price of IRON increased from $66.08 to a 52-week high of $95.95 [5] Clinical Trials and Data Readouts - Mind Medicine Inc. (MNMD) is preparing for pivotal data readouts in 2026 for its lead drug candidate, MM120 ODT, with results expected from multiple phase 3 trials [6][7] - MNMD's stock rose from $7.69 to a 52-week high of $13.86 [8] - Atai Life Sciences N.V. (ATAI) is progressing towards shareholder approval for its combination with Beckley Psytech Limited, aiming to lead in psychedelic-based mental health therapies [8] - ATAI's stock increased from $2.35 to a 52-week high of $6.55 [12] Ongoing Studies and Future Expectations - Assembly Biosciences Inc. (ASMB) is advancing its four key development programs, with ABI-5366 in a Phase 1b study for recurrent genital herpes [12][13] - ASMB's stock rose from $14.53 to a 52-week high of $30.20 [15] - Belite Bio Inc. (BLTE) is expected to report final topline data from the phase 3 DRAGON trial for its lead candidate, Tinlarebant, this quarter [16] - BLTE's stock increased from $69.60 to an all-time high of $91.92 [16] Earnings Expectations - Aveanna Healthcare Holdings Inc. (AVAH) is set to release its third-quarter results, with analysts expecting earnings of $0.08 per share on revenue of $577.01 million [17] - AVAH's stock rose from $5.35 to a 52-week high of $10.23 [18] Significant Trial Results - Nektar Therapeutics (NKTR) reported positive data from its phase 2b REZOLVE-AD trial for atopic dermatitis, with 52-week data expected in early 2026 [19][21] - NKTR's stock increased from $11.25 to a 52-week high of $63.92 [21]

Core Insights - The article highlights stocks reaching new 52-week highs, indicating market recognition of strong fundamentals and potential catalysts for growth [1][2]. Company Summaries Cogent Biosciences Inc. (COGT) - Cogent Biosciences plans to file its first New Drug Application for Bezuclastinib by the end of 2025, targeting non-advanced systemic mastocytosis [3]. - A phase III trial comparing Bezuclastinib with Sutent is ongoing, with results expected in the second half of 2025 [4]. - The stock reached a 52-week high of $16.99, up from $7.25 when last featured [5]. Assembly Biosciences Inc. (ASMB) - Assembly Biosciences is advancing four key development programs, with ABI-5366 expected to enter phase 2 studies in mid-2026 [6]. - Interim data for ABI-1179 is anticipated this fall, while ABI-6250 is in a phase 1a trial [7]. - The stock hit a 52-week high of $28, up from $14.53 when last featured [8]. Compass Therapeutics Inc. (CMPX) - Compass Therapeutics is conducting a phase 2/3 study of Tovecimig for advanced biliary tract cancer, with analyses of secondary endpoints expected in Q1 2026 [9][10]. - The stock reached a 52-week high of $4.39, up from $2.91 when last featured [11]. NewAmsterdam Pharma Company N.V. (NAMS) - NewAmsterdam Pharma is developing Obicetrapib as a cholesterol-lowering therapy, with positive data from the BROADWAY trial [12][13]. - The company has completed two additional phase III trials and submitted marketing applications to the EMA [16]. - The stock reached a 52-week high of $39.76, up from $21.56 when last featured [17]. Mineralys Therapeutics Inc. (MLYS) - Mineralys is developing Lorundrostat for uncontrolled hypertension, with a pivotal phase III trial achieving its primary endpoint [19]. - A phase II trial for overweight participants with OSA is ongoing, with topline results expected in 1H 2026 [20]. - The stock hit a 52-week high of $43.88, up from $10.34 when last featured [20]. Kymera Therapeutics Inc. (KYMR) - Kymera is set to report data from its phase I trial of KT-621 this quarter, with phase 2b studies planned for late 2025 and early 2026 [21][22]. - The stock reached a 52-week high of $60, up from $40 when last featured [22]. Insmed Inc. (INSM) - Insmed has two approved drugs and is conducting a phase 3 trial of Arikayce, with topline results expected in 1H 2026 [24][25]. - The stock hit a high of $166.54, up from $76.54 when last featured [26]. Adaptive Biotechnologies Corp. (ADPT) - Adaptive Biotechnologies expects MRD revenue between $190 million and $200 million for 2025, up from $145.5 million in 2024 [28][29]. - The stock reached a 52-week high of $15.94, up from $9.80 when last featured [29]. BridgeBio Pharma Inc. (BBIO) - BridgeBio has upcoming topline results from the FORTIFY and CALIBRATE studies expected in Fall 2025 [30]. - The stock reached a 3-year high of $56.24, up from $25.10 when last featured [31]. Tarsus Pharmaceuticals Inc. (TARS) - Tarsus reported strong sales for Xdemvy, with Q2 2025 sales of $102.7 million, compared to $40.8 million in Q2 2024 [32]. - The stock hit an all-time high of $70.15, up from $25.01 when last featured [34]. Palvella Therapeutics Inc. (PVLA) - Palvella's QTORIN is under development for various skin diseases, with a phase 2 trial expected to report data in mid-December 2025 [35][36]. - The stock reached a 52-week high of $76.76, up from $25 when last featured [36]. Merus N.V. (MRUS) - Merus agreed to be acquired by Genmab for $97 per share, with the deal expected to close in early Q1 2026 [37]. - The stock was at $39.71 when last featured [39]. Nephros Inc. (NEPH) - Nephros reported net revenue of $4.4 million for Q2 2025, marking its third consecutive quarter of profitability [40][41]. - The stock hit a 52-week high of $5.98, up from $2.93 when last featured [42].

Core Insights - Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, indicating strong technical strength and price action [1][2] Group 1: Momentum Ranking - Arrowhead Pharmaceuticals Inc. (ARWR), Assembly Biosciences Inc. (ASMB), Atara Biotherapeutics Inc. (ATRA), and Corcept Therapeutics Inc. (CORT) have shown significant momentum percentile increases, making them stand out in the competitive biotech sector [2][5] - Joining the top decile for momentum ranking means these stocks are outperforming 90% of all tracked stocks in terms of price appreciation and volatility-adjusted returns [5] Group 2: Individual Stock Performance - ARWR's momentum percentile increased from 89.87 to 93.79, with a week-on-week gain of 3.92 percentage points; the stock has risen by 66.92% year-to-date and 69.33% over the year [7] - ASMB moved from 87.58 to 93.13, posting a 5.55 percentage point increase; it is up 43.85% YTD and 62.95% over the year [7] - ATRA climbed from 88.24 to 92.76, translating to a weekly gain of 4.52 percentage points; the stock has declined 2.97% YTD but advanced 69.00% over the year [8] - CORT advanced from 88.05 to 90.50, achieving a week-on-week improvement of 2.45 percentage points; it has risen by 67.84% YTD and 81.22% over the year [8]